• Trade
  • Markets
  • Copy
  • Contests
  • News
  • 24/7
  • Calendar
  • Q&A
  • Chats
Trending
Screeners
SYMBOL
LAST
BID
ASK
HIGH
LOW
NET CHG.
%CHG.
SPREAD
SPX
S&P 500 Index
6870.39
6870.39
6870.39
6895.79
6858.28
+13.27
+ 0.19%
--
DJI
Dow Jones Industrial Average
47954.98
47954.98
47954.98
48133.54
47871.51
+104.05
+ 0.22%
--
IXIC
NASDAQ Composite Index
23578.12
23578.12
23578.12
23680.03
23506.00
+72.99
+ 0.31%
--
USDX
US Dollar Index
98.950
99.030
98.950
99.060
98.740
-0.030
-0.03%
--
EURUSD
Euro / US Dollar
1.16426
1.16443
1.16426
1.16715
1.16277
-0.00019
-0.02%
--
GBPUSD
Pound Sterling / US Dollar
1.33312
1.33342
1.33312
1.33622
1.33159
+0.00041
+ 0.03%
--
XAUUSD
Gold / US Dollar
4197.91
4197.91
4197.91
4259.16
4191.87
-9.26
-0.22%
--
WTI
Light Sweet Crude Oil
59.809
60.061
59.809
60.236
59.187
+0.426
+ 0.72%
--

Community Accounts

Signal Accounts
--
Profit Accounts
--
Loss Accounts
--
View More

Become a signal provider

Sell trading signals to earn additional income

View More

Guide to Copy Trading

Get started with ease and confidence

View More

Signal Accounts for Members

All Signal Accounts

Best Return
  • Best Return
  • Best P/L
  • Best MDD
Past 1W
  • Past 1W
  • Past 1M
  • Past 1Y

All Contests

  • All
  • Trump Updates
  • Recommend
  • Stocks
  • Cryptocurrencies
  • Central Banks
  • Featured News
Top News Only
Share

Putin, Modi Agree To Expand And Widen India-Russia Trade, Strengthen Friendship

Share

Colombia Inflation Was +0.07% In November -Government Statistics Agency (Reuters Poll: +0.20%)

Share

Colombia 12-Month Inflation Was +5.30% In November -Government Statistics Agency (Reuters Poll: +5.45%)

Share

White House: US, Ukraine Officials Had Productive Meeting, Further Talks Set

Share

Pentagon - State Department Approves Potential Sale Of Small Diameter Bombs-Increment I And Related Equipment To South Korea For $111.8 Million

Share

US State Dept: Parties Will Reconvene Tomorrow To Continue Advancing Discussions

Share

US State Dept: Parties Agreed That Real Progress Toward Any Agreement Depends On Russia's Readiness To Show Serious Commitment To Long-Term Peace

Share

US State Dept: Parties Also Separately Reviewed Future Prosperity Agenda

Share

US State Dept: American And Ukrainians Also Agreed On Framework Of Security Arrangements And Discussed Necessary Deterrence Capabilities

Share

US State Dept: Participants Discussed Results Of Recent Meeting Of American Side With Russians And Steps That Could Lead To Ending This War

Share

US State Dept: Umerov Reaffirmed That Ukraine's Priority Is Securing A Settlement That Protects Its Independence And Sovereignty

Share

Pentagon: US State Dept Approves Potential Sale Of Joint Air-To-Surface Standoff Missiles With Extended Range To Italy For An Estimated Cost Of $301 Million

Share

EU Commission Chief Von Der Leyen, Germany's Merz Say They Held 'Constructive' Talks With Belgian Prime Minister De Wever On Russian Frozen Assets

Share

Pentagon: US State Dept Approves Sale Of Aim-120C-8 Advanced Medium Range Air-To-Air Missiles To Denmark For An Estimated Cost Of $730 Million

Share

U.S. Senate Republican Senator Marshall (echoing The Trump Administration's Position): Netflix's Acquisition Of Warner Bros. Discovery Is A "serious Red Flag."

Share

SPDR Gold Trust Reports Holdings Down 0.03%, Or 0.33 Tonnes, To 1050.25 Tonnes By Dec 5

Share

The Canadian Prime Minister's Office: The Meeting Between Prime Minister Carney, US President Trump, And Mexican President Sinbaum Lasted 45 Minutes

Share

S&P Dow Jones Indices: Crh, Carvana, And Comfort Systems USA Will Be Included In The S&P 500 Index

Share

Waymo, The Self-driving Car Division Of Google's Parent Company Alphabet, Has Voluntarily Applied To The National Highway Traffic Safety Administration (NHTSA) For A Software Recall

Share

Fitch On Hungary: Frequent Revisions To Government's Targets Have Weakened Policy Predictability And Increased Fiscal Risks

TIME
ACT
FCST
PREV
Italy Retail Sales MoM (SA) (Oct)

A:--

F: --

P: --

Euro Zone Employment YoY (SA) (Q3)

A:--

F: --

P: --

Euro Zone GDP Final YoY (Q3)

A:--

F: --

P: --

Euro Zone GDP Final QoQ (Q3)

A:--

F: --

P: --

Euro Zone Employment Final QoQ (SA) (Q3)

A:--

F: --

P: --

Euro Zone Employment Final (SA) (Q3)

A:--

F: --

P: --
Brazil PPI MoM (Oct)

A:--

F: --

P: --

Mexico Consumer Confidence Index (Nov)

A:--

F: --

P: --

Canada Unemployment Rate (SA) (Nov)

A:--

F: --

P: --

Canada Labor Force Participation Rate (SA) (Nov)

A:--

F: --

P: --

Canada Employment (SA) (Nov)

A:--

F: --

P: --

Canada Part-Time Employment (SA) (Nov)

A:--

F: --

P: --

Canada Full-time Employment (SA) (Nov)

A:--

F: --

P: --

U.S. Personal Income MoM (Sept)

A:--

F: --

P: --

U.S. PCE Price Index YoY (SA) (Sept)

A:--

F: --

P: --

U.S. PCE Price Index MoM (Sept)

A:--

F: --

P: --

U.S. Personal Outlays MoM (SA) (Sept)

A:--

F: --

P: --

U.S. Core PCE Price Index MoM (Sept)

A:--

F: --

P: --

U.S. Core PCE Price Index YoY (Sept)

A:--

F: --

P: --

U.S. UMich 5-Year-Ahead Inflation Expectations Prelim YoY (Dec)

A:--

F: --

P: --

U.S. Real Personal Consumption Expenditures MoM (Sept)

A:--

F: --

P: --

U.S. 5-10 Year-Ahead Inflation Expectations (Dec)

A:--

F: --

P: --

U.S. UMich Current Economic Conditions Index Prelim (Dec)

A:--

F: --

P: --

U.S. UMich Consumer Sentiment Index Prelim (Dec)

A:--

F: --

P: --

U.S. UMich 1-Year-Ahead Inflation Expectations Prelim (Dec)

A:--

F: --

P: --

U.S. UMich Consumer Expectations Index Prelim (Dec)

A:--

F: --

P: --

U.S. Weekly Total Rig Count

A:--

F: --

P: --

U.S. Weekly Total Oil Rig Count

A:--

F: --

P: --

U.S. Unit Labor Cost Prelim (SA) (Q3)

--

F: --

P: --

U.S. Consumer Credit (SA) (Oct)

A:--

F: --

P: --

China, Mainland Foreign Exchange Reserves (Nov)

--

F: --

P: --

China, Mainland Exports YoY (USD) (Nov)

--

F: --

P: --

China, Mainland Imports YoY (CNH) (Nov)

--

F: --

P: --

China, Mainland Imports YoY (USD) (Nov)

--

F: --

P: --

China, Mainland Imports (CNH) (Nov)

--

F: --

P: --

China, Mainland Trade Balance (CNH) (Nov)

--

F: --

P: --

China, Mainland Exports (Nov)

--

F: --

P: --

Japan Wages MoM (Oct)

--

F: --

P: --

Japan Trade Balance (Oct)

--

F: --

P: --

Japan Nominal GDP Revised QoQ (Q3)

--

F: --

P: --

Japan Trade Balance (Customs Data) (SA) (Oct)

--

F: --

P: --

Japan GDP Annualized QoQ Revised (Q3)

--

F: --

P: --
China, Mainland Exports YoY (CNH) (Nov)

--

F: --

P: --

China, Mainland Trade Balance (USD) (Nov)

--

F: --

P: --

Germany Industrial Output MoM (SA) (Oct)

--

F: --

P: --

Euro Zone Sentix Investor Confidence Index (Dec)

--

F: --

P: --

Canada Leading Index MoM (Nov)

--

F: --

P: --

Canada National Economic Confidence Index

--

F: --

P: --

U.S. Dallas Fed PCE Price Index YoY (Sept)

--

F: --

P: --

U.S. 3-Year Note Auction Yield

--

F: --

P: --

U.K. BRC Overall Retail Sales YoY (Nov)

--

F: --

P: --

U.K. BRC Like-For-Like Retail Sales YoY (Nov)

--

F: --

P: --

Australia Overnight (Borrowing) Key Rate

--

F: --

P: --

RBA Rate Statement
RBA Press Conference
Germany Exports MoM (SA) (Oct)

--

F: --

P: --

U.S. NFIB Small Business Optimism Index (SA) (Nov)

--

F: --

P: --

Mexico Core CPI YoY (Nov)

--

F: --

P: --

Mexico 12-Month Inflation (CPI) (Nov)

--

F: --

P: --

Mexico PPI YoY (Nov)

--

F: --

P: --

Q&A with Experts
    • All
    • Chatrooms
    • Groups
    • Friends
    Connecting
    .
    .
    .
    Type here...
    Add Symbol or Code

      No matching data

      All
      Trump Updates
      Recommend
      Stocks
      Cryptocurrencies
      Central Banks
      Featured News
      • All
      • Russia-Ukraine Conflict
      • Middle East Flashpoint
      • All
      • Russia-Ukraine Conflict
      • Middle East Flashpoint
      Search
      Products

      Charts Free Forever

      Chats Q&A with Experts
      Screeners Economic Calendar Data Tools
      Membership Features
      Data Warehouse Market Trends Institutional Data Policy Rates Macro

      Market Trends

      Market Sentiment Order Book Forex Correlations

      Top Indicators

      Charts Free Forever
      Markets

      News

      News Analysis 24/7 Columns Education
      From Institutions From Analysts
      Topics Columnists

      Latest Views

      Latest Views

      Trending Topics

      Top Columnists

      Latest Update

      Signals

      Copy Rankings Latest Signals Become a signal provider AI Rating
      Contests
      Brokers

      Overview Brokers Assessment Rankings Regulators News Claims
      Broker listing Forex Brokers Comparison Tool Live Spread Comparison Scam
      Q&A Complaint Scam Alert Videos Tips to Detect Scam
      More

      Business
      Events
      Careers About Us Advertising Help Center

      White Label

      Data API

      Web Plug-ins

      Affiliate Program

      Awards Institution Evaluation IB Seminar Salon Event Exhibition
      Vietnam Thailand Singapore Dubai
      Fans Party Investment Sharing Session
      FastBull Summit BrokersView Expo
      Recent Searches
        Top Searches
          Markets
          News
          Analysis
          User
          24/7
          Economic Calendar
          Education
          Data
          • Names
          • Latest
          • Prev

          View All

          No data

          Scan to Download

          Faster Charts, Chat Faster!

          Download App
          English
          • English
          • Español
          • العربية
          • Bahasa Indonesia
          • Bahasa Melayu
          • Tiếng Việt
          • ภาษาไทย
          • Français
          • Italiano
          • Türkçe
          • Русский язык
          • 简中
          • 繁中
          Open Account
          Search
          Products
          Charts Free Forever
          Markets
          News
          Signals

          Copy Rankings Latest Signals Become a signal provider AI Rating
          Contests
          Brokers

          Overview Brokers Assessment Rankings Regulators News Claims
          Broker listing Forex Brokers Comparison Tool Live Spread Comparison Scam
          Q&A Complaint Scam Alert Videos Tips to Detect Scam
          More

          Business
          Events
          Careers About Us Advertising Help Center

          White Label

          Data API

          Web Plug-ins

          Affiliate Program

          Awards Institution Evaluation IB Seminar Salon Event Exhibition
          Vietnam Thailand Singapore Dubai
          Fans Party Investment Sharing Session
          FastBull Summit BrokersView Expo

          Halper Sadeh Llc Encourages Gifi, Avdl, Jamf, Cde Shareholders To Contact The Firm To Discuss Their Rights

          Reuters
          Avadel Pharmaceuticals
          -0.07%
          Coeur Mining
          -1.49%
          Gulf Island Fabrication
          -0.04%
          Jamf Holding
          -0.04%
          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          $Hareholder Alert: The M&A Class Action Firm Continues To Investigate The Merger—Gifi, Avdl, Smlr, And Cde

          Reuters
          Avadel Pharmaceuticals
          -0.07%
          Coeur Mining
          -1.49%
          Gulf Island Fabrication
          -0.04%
          Semler Scientific
          -7.98%
          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          REG - BlackRock Group Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plc

          London Stock Exchange
          Avadel Pharmaceuticals
          -0.07%
          Blackrock
          +0.17%
          RNS Number : 2885K BlackRock Group 04 December 2025  

          FORM 8.3

          IRISH TAKEOVER PANEL

          OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

          RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

          1.             KEY INFORMATION

          (a)   Full name of discloser

          BlackRock, Inc.

          (b)   Owner or controller of interests and short positions disclosed, if different from 1(a)

          The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

          N/A

          (c)   Name of offeror/offeree in relation to whose relevant securities this form relates

          Use a separate form for each offeror/offeree

          Avadel Pharmaceuticals plc

          (d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)

          (e)   Date position held/dealing undertaken

          For an opening position disclosure, state the latest practicable date prior to the disclosure

          03 December 2025

          (f)    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?

          If it is a cash offer or possible cash offer, state "N/A"

          N/A

          2.             INTERESTS AND SHORT POSITIONS

          If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

          Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

          (Note 2)

          Class of relevant security

          (Note 3)

          $0.01 ordinary shares

          Interests

          Short positions

          Number

          %

          Number

          %

          (1)   Relevant securities owned and/or controlled

          6,823,149

          6.95%

          2,934

          0.00%

          (2)   Cash-settled derivatives

          0

          0.00%

          4,268

          0.00%

          (3)   Stock-settled derivatives (including options) and agreements to purchase/ sell

          0

          0.00%

          0

          0.00%

          Total

          6,823,149

          6.95%

          7,202

          0.00%

          All interests and all short positions should be disclosed.

          Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

          3.             DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

          Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

          The currency of all prices and other monetary amounts should be stated.

          (a)           Purchases and sales

          Class of relevant security

          $0.01 ordinary shares

          Purchase/sale

          Sale

          Number of securities

          1,230

          Price per unit

          (Note 5)

          USD 21.3600

          (b)           Cash-settled derivative transactions

          • Class of relevant security

          • Product

            description

            e.g. CFD

          • Nature of dealing

            e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position

          • Number of

            reference

            securities

            (Note 6)

          • Price

            per unit

            (Note 5)

          (c)           Stock-settled derivative transactions (including options)

          (i)            Writing, selling, purchasing or varying

          • Class of relevant security

          • Product

            description e.g. call

            option

          • Writing, purchasing, selling, varying

            etc.

          • Number of

            securities to which option relates (Note 6)

          • Exercise

            price per

            unit

          • Type

            e.g. American,

            European etc.

          • Expiry

            date

          • Option money

            paid/

            received per unit

          (ii)           Exercise

          • Class of relevant security

          • Product description

            e.g. call option

          • Exercising/

            exercised against

          • Number of securities

          • Exercise price per unit (Note 5)

          (d)           Other dealings (including transactions in respect of new securities) (Note 3)

          Class of relevant

          security

          Nature of dealing

          e.g. subscription, conversion, exercise

          Details

          Price per unit (if applicable)

          (Note 5)

          $0.01 ordinary shares

          Stock on Loan

          76,800

          N/A

          $0.01 ordinary shares

          Return of Stock on Loan

          17,900

          N/A

          $0.01 ordinary shares

          Transfer in of Shares

          19,482

          N/A

          4.             OTHER INFORMATION

          (a)           Indemnity and other dealing arrangements

          Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.

          Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

          (b)           Agreements, arrangements or understandings relating to options or derivatives

          Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

          (c)           Attachments

          • Is a Supplemental Form 8 attached?

          • NO

          Date of disclosure

          04 December 2025

          Contact name

          Jana Blumenstein

          Telephone number

          +44 20 7743 3650

          Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

          NOTES ON FORM 8.3

          1.             See the definition of "connected fund manager" in Rule 2.2 of Part A of the Rules.

          2.             See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.

          3.             See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.

          4.             See the definition of "dealing" in Rule 2.1 of Part A of the Rules.

          5.             If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

          6.             See Rule 2.5(d) of Part A of the Rules.

          7.             If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

          For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

          References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

          This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

          RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  ITPPKQBBKBDDDBK

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          REG - BkofA Merrill Lynch Avadel Pharma plc - Form 8.3-Avadel Pharmaceuticals plc

          London Stock Exchange
          Avadel Pharmaceuticals
          -0.07%
          Bank of America
          +0.13%
          RNS Number : 3126K Bank of America Merrill Lynch 04 December 2025  

          FORM 8.3

          IRISH TAKEOVER PANEL

          OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

          RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

          1.             KEY INFORMATION

          (a)   Full name of discloser

          Bank of America Corporation

          (b)   Owner or controller of interests and short positions disclosed, if different from 1(a)

          The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

          (c)   Name of offeror/offeree in relation to whose relevant securities this form relates

          Use a separate form for each offeror/offeree

          AVADEL PHARMACEUTICALS PLC

          (d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)

          (e)   Date position held/dealing undertaken

          For an opening position disclosure, state the latest practicable date prior to the disclosure

          03/12/2025

          (f)    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?

          If it is a cash offer or possible cash offer, state "N/A"

          No

          2.             INTERESTS AND SHORT POSITIONS

          If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

          Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

          (Note 2)

          Class of relevant security

          (Note 3)

          0.01 ordinary shares

          Interests

          Short positions

          Number

          %

          Number

          %

          (1)   Relevant securities owned and/or controlled

          2,804,362

          2.879%

          1,065,284

          1.094%

          (2)   Cash-settled derivatives

          141,124

          0.145%

          786,245

          0.807%

          (3)   Stock-settled derivatives (including options) and agreements to purchase/ sell

          0

          0.000%

          0

          0.000%

          Total

          2,945,486

          3.024%

          1,851,529

          1.901%

          All interests and all short positions should be disclosed.

          Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

          3.             DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

          Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

          The currency of all prices and other monetary amounts should be stated.

          (a)           Purchases and sales

          Class of relevant

          security

          Purchase/sale

          Number of

          securities

          Price per unit

          (Note 5)

          USD 0.01 common

          Purchase

          60

          21.35 USD

          USD 0.01 common

          Purchase

          12

          21.355 USD

          USD 0.01 common

          Purchase

          3

          21.356667 USD

          USD 0.01 common

          Purchase

          124

          21.36 USD

          USD 0.01 common

          Purchase

          7

          21.37 USD

          USD 0.01 common

          Purchase

          55

          21.372546 USD

          USD 0.01 common

          Purchase

          24

          21.38 USD

          USD 0.01 common

          Purchase

          6

          21.39 USD

          USD 0.01 common

          Purchase

          35

          21.4 USD

          USD 0.01 common

          Purchase

          4

          21.405 USD

          USD 0.01 common

          Purchase

          22

          21.35 USD

          USD 0.01 common

          Purchase

          3,755

          21.355 USD

          USD 0.01 common

          Purchase

          7,885

          21.36 USD

          Class of relevant

          security

          Purchase/sale

          Number of

          securities

          Price per unit

          (Note 5)

          USD 0.01 common

          Sale

          18

          21.35 USD

          USD 0.01 common

          Sale

          42

          21.355 USD

          USD 0.01 common

          Sale

          3

          21.356667 USD

          USD 0.01 common

          Sale

          128

          21.36 USD

          USD 0.01 common

          Sale

          22560

          21.364301 USD

          USD 0.01 common

          Sale

          4

          21.365 USD

          USD 0.01 common

          Sale

          3

          21.366667 USD

          USD 0.01 common

          Sale

          25

          21.37 USD

          USD 0.01 common

          Sale

          55

          21.372546 USD

          USD 0.01 common

          Sale

          4

          21.375 USD

          USD 0.01 common

          Sale

          56

          21.38 USD

          USD 0.01 common

          Sale

          2

          21.39 USD

          USD 0.01 common

          Sale

          11

          21.4 USD

          USD 0.01 common

          Sale

          40

          21.36 USD

          (b)           Cash-settled derivative transactions

          Class of

          relevant

          security

          Product

          description

          e.g. CFD

          Nature of dealing

          e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position

          Number of

          reference

          securities

          (Note 6)

          Price

          per unit

          (Note 5)

           USD

          USD 0.01 common

          Swaps

          Reducing a short position

          11,713

          21.3629 USD

          USD 0.01 common

          Swaps

          Reducing a short position

          458

          21.3629 USD

          USD 0.01 common

          Swaps

          Reducing a short position

          1,170

          21.3629 USD

          USD 0.01 common

          Swaps

          Increasing a long position

          348

          21.3629 USD

          USD 0.01 common

          Swaps

          Reducing a short position

          1,786

          21.3629 USD

          USD 0.01 common

          Swaps

          Reducing a short position

          1,846

          21.3629 USD

          USD 0.01 common

          Swaps

          Reducing a short position

          1,049

          21.3629 USD

          USD 0.01 common

          Swaps

          Reducing a short position

          4,190

          21.3629 USD

          (c)           Stock-settled derivative transactions (including options)

          (i)            Writing, selling, purchasing or varying

          Class of

          relevant

          security

          N/A

          Product

          description e.g. call

          option

          N/A

          Writing, purchasing, selling, varying

          etc.

          N/A

          Number

          of

          securities

          to which

          option

          relates

          (Note 6)

          N/A

          Exercise

          price per

          unit

          N/A

          Type

          e.g.

          American,

          European

          etc.

          N/A

          Expiry

          date

          N/A

          Option

          money

          paid/

          received per unit

          N/A

          (ii)           Exercise

          Class of

          relevant

          security

          N/A

          Product

          description

          e.g. call

          option

          N/A

          Exercising/

          exercised

          against

          N/A

          Number of

          securities

          N/A

          Exercise

          price per

          unit

          (Note 5)

          N/A

          (d)           Other dealings (including transactions in respect of new securities) (Note 3)

          Class of

          relevant

          security

          N/A

          Nature of dealing

          e.g. subscription,

          conversion, exercise

          N/A

          Details

          N/A

          Price per unit (if

          applicable)

          (Note 5)

          N/A

          4.             OTHER INFORMATION

          (a)           Indemnity and other dealing arrangements

          Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.

          Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

          (b)           Agreements, arrangements or understandings relating to options or derivatives

          Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

          (c)           Attachments

          • Is a Supplemental Form 8 attached?

          • No

          Date of disclosure

          04/12/2025

          Contact name

          Kamil Dziedzic

          Telephone number

          +353 86 168 4821

          Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

          This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

          RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  ITPLZLFBELLFFBV

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          REG - Goldman Sachs & Co. Avadel Pharma plc - Form 38.5b - Avadel Pharmaceuticals plc

          London Stock Exchange
          Avadel Pharmaceuticals
          -0.07%
          Goldman Sachs
          +2.00%
          RNS Number : 3087K Goldman Sachs & Co. LLC 04 December 2025  

           

          FORM 38.5(b)

          IRISH TAKEOVER PANEL

          DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

          DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

          1. KEY INFORMATION

          Name of exempt principal trader

          GOLDMAN SACHS & CO. LLC

          Company dealt in

          AVADEL PHARMACEUTICALS PLC

          Class of relevant security to which the dealings being disclosed relate (Note1)

          USD 0.01 ordinary shares

          Date of dealing

          03 December 2025

          2. INTERESTS AND SHORT POSITIONS

          (a) Interests and short positions (following dealing) in the class of relevant security dealt in  (Note 2)

          Long

          Short

          Number

          (%)

          Number

          (%)

          (1) Relevant securities

          937,042

          (0.96)

          499,947

          (0.51)

          (2) Derivatives (other than options)

          63,546

          (0.06)

          63,843

          (0.06)

          (3) Options and agreements to purchase/sell

          0

          (0.00)

          0

          (0.00)

          Total

          1,000,588

          (1.02)

          563,790

          (0.57)

          (b) Interests and short positions in relevant securities of the company, other than the class dealt in  (Note 2)

          Class of relevant security:

          Long

          Short

          Number

          (%)

          Number

          (%)

          (1) Relevant securities

          (2) Derivatives (other than options)

          (3) Options and agreements to purchase/sell

          Total

          3.    DEALINGS (Note 3)

          (a) Purchases and sales

          Purchase/sale

          Number of relevant securities

          Price per unit  (Note 4)

          Purchase

          100

          21.3500 USD

          Purchase

          100

          21.3500 USD

          Purchase

          100

          21.3550 USD

          Purchase

          100

          21.3550 USD

          Purchase

          927

          21.3550 USD

          Purchase

          100

          21.3550 USD

          Purchase

          100

          21.3550 USD

          Purchase

          127

          21.3550 USD

          Purchase

          100

          21.3550 USD

          Purchase

          100

          21.3550 USD

          Sale (Borrow Partial Return)

          11,700

          N/A

          Sale (Borrow Full Return)

          31,600

          N/A

          Purchase (Loan Full Return)

          423

          N/A

          Purchase (Loan Full Return)

          265

          N/A

          Purchase (Borrow New)

          1,177

          N/A

          Sale (Borrow Full Return)

          1,177

          N/A

          Purchase (Borrow New)

          3,000

          N/A

          Purchase (Borrow New)

          1,500

          N/A

          Purchase (Borrow New)

          72,900

          N/A

          Purchase (Borrow New)

          3,000

          N/A

          Purchase (Borrow New)

          1,177

          N/A

          Sale (Borrow Partial Return)

          49

          N/A

          Sale (Borrow Full Return)

          55,800

          N/A

          Purchase (Borrow New)

          7,000

          N/A

          (b) Derivatives transactions (other than options transactions)

          Product name, e.g. CFD

          Nature of transaction  (Note 5)

          Number of relevant securities  (Note 6)

          Price per unit  (Note 4)

          CFD

          Reducing a long position

          76

          21.3630 USD

          CFD

          Reducing a long position

          1,480

          21.3706 USD

          (c) Options transactions in respect of existing relevant securities

          (i) Writing, selling, purchasing or varying

          • Product name,e.g. call option

          • Writing, selling,  purchasing, varying etc.

          • Number of securities to which the option relates  (Note 7)

          • Exercise price

          • Type, e.g. American, European etc.

          • Expiry date

          • Option money paid/received per unit  (Note 4)

          (ii)            Exercising

          • Product name,e.g. call option

          • Number of securities

          • Exercise price per unit  (Note 4)

          (d)            Other dealings (including transactions in respect of new securities)  (Note 3)

          • Nature of transaction  (Note 7)

          • Details

          • Price per unit (if applicable)  (Note 4)

          4. OTHER INFORMATION

          Agreements, arrangements or understandings relating to options or derivatives

          • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.  If none, this should be stated. 

          • NONE

          Is a Supplemental Form 8 attached? (Note 9)        YES

          Date of disclosure

          04 December 2025

          Contact name

          Papa Lette and Andrzej Szyszka

          Telephone number

          +33(1) 4212 1459 / +48(22) 317 4817

          Name of offeree/offeror with which connected

          AVADEL PHARMACEUTICALS PLC

          Nature of connection (Note 9)

          Advisor to Offeree

          SUPPLEMENTAL FORM 38.5(b)

          IRISH TAKEOVER PANEL

          DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

          DETAILS OF OPEN POSITIONS

          OPEN POSITIONS (Note 1)

          Product name,e.g. call option

          Written or purchased

          Number of relevant securities to which the option or derivative relates

          Exercise price (Note 2)

          Type, e.g. American, European etc.

          Expiry date

          Swap

          Sold

          84

          0.0000

          N/A

          17/12/2025

          Swap

          Purchased

          33,762

          0.0000

          N/A

          20/01/2026

          Notes

          1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

          2. For all prices and other monetary amounts, the currency must be stated.

          For full details of disclosure requirements, see Rules 8 and 38.5 of the Rules. If in doubt, consult the Panel.

          This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

          RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  ITPUPGQAPUPAGGC

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          REG - Goldman Sachs (EPT) Avadel Pharma plc - Form 38.5b - Avadel Pharmaceuticals plc

          London Stock Exchange
          Avadel Pharmaceuticals
          -0.07%
          Goldman Sachs
          +2.00%
          RNS Number : 3091K GoldmanSachs International 04 December 2025  

           

          FORM 38.5(b)

          IRISH TAKEOVER PANEL

          DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

          DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

          1. KEY INFORMATION

          Name of exempt principal trader

          (GS) GOLDMAN SACHS INTERNATIONAL

          Company dealt in

          AVADEL PHARMACEUTICALS PLC

          Class of relevant security to which the dealings being disclosed relate (Note1)

          USD 0.01 ordinary shares

          Date of dealing

          03 December 2025

          2. INTERESTS AND SHORT POSITIONS

          (a) Interests and short positions (following dealing) in the class of relevant security dealt in  (Note 2)

          Long

          Short

          Number

          (%)

          Number

          (%)

          (1) Relevant securities

          53

          (0.00)

          1,128

          (0.00)

          (2) Derivatives (other than options)

          0

          (0.00)

          0

          (0.00)

          (3) Options and agreements to purchase/sell

          0

          (0.00)

          0

          (0.00)

          Total

          53

          (0.00)

          1,128

          (0.00)

          (b) Interests and short positions in relevant securities of the company, other than the class dealt in  (Note 2)

          Class of relevant security:

          Long

          Short

          Number

          (%)

          Number

          (%)

          (1) Relevant securities

          (2) Derivatives (other than options)

          (3) Options and agreements to purchase/sell

          Total

          3.    DEALINGS (Note 3)

          (a) Purchases and sales

          Purchase/sale

          Number of relevant securities

          Price per unit  (Note 4)

          Sale (Borrow Full Return)

          423

          N/A

          Purchase (Loan Full Return)

          1,177

          N/A

          Sale (Loan New)

          1,177

          N/A

          Sale (Borrow Full Return)

          265

          N/A

          Sale (Loan New)

          1,177

          N/A

          Purchase (Loan Partial Return)

          49

          N/A

          (b) Derivatives transactions (other than options transactions)

          • Product name, e.g. CFD

          • Nature of transaction  (Note 5)

          • Number of relevant securities  (Note 6)

          • Price per unit  (Note 4)

          (c) Options transactions in respect of existing relevant securities

          (i) Writing, selling, purchasing or varying

          • Product name,e.g. call option

          • Writing, selling,  purchasing, varying etc.

          • Number of securities to which the option relates  (Note 7)

          • Exercise price

          • Type, e.g. American, European etc.

          • Expiry date

          • Option money paid/received per unit  (Note 4)

          (ii)            Exercising

          • Product name,e.g. call option

          • Number of securities

          • Exercise price per unit  (Note 4)

          (d)            Other dealings (including transactions in respect of new securities)  (Note 3)

          • Nature of transaction  (Note 7)

          • Details

          • Price per unit (if applicable)  (Note 4)

          4. OTHER INFORMATION

          Agreements, arrangements or understandings relating to options or derivatives

          • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.  If none, this should be stated. 

          • NONE

          Is a Supplemental Form 8 attached? (Note 9)        NO

          Date of disclosure

          04 December 2025

          Contact name

          Papa Lette and Andrzej Szyszka

          Telephone number

          +33(1) 4212 1459 / +48(22) 317 4817

          Name of offeree/offeror with which connected

          AVADEL PHARMACEUTICALS PLC

          Nature of connection (Note 9)

          Advisor to Offeree

          This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

          RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  ITPUPGMAPUPAGGC

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          REG - Janus Henderson Inv. Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plc

          London Stock Exchange
          Avadel Pharmaceuticals
          -0.07%
          Janus Henderson Group
          +0.79%
          RNS Number : 2976K Janus Henderson Investors 04 December 2025  

          Ap27

          FORM 8.3

          IRISH TAKEOVER PANEL

          OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

          RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

          1.             KEY INFORMATION

          (a)   Full name of discloser

          Janus Henderson Group plc

          (b)   Owner or controller of interests and short positions disclosed, if different from 1(a)

          The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

          (c)   Name of offeror/offeree in relation to whose relevant securities this form relates

          Use a separate form for each offeror/offeree

          Avadel Pharmaceuticals plc

          (d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)

          (e)   Date position held/dealing undertaken

          For an opening position disclosure, state the latest practicable date prior to the disclosure

          03 December 2025

          (f)    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?

          If it is a cash offer or possible cash offer, state "N/A"

          N/A

          2.             INTERESTS AND SHORT POSITIONS

          If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

          Ap28

          Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

          (Note 2)

          Class of relevant security

          (Note 3)

          $0.01 ordinary shares

          Interests

          Short positions

          Number

          %

          Number

          %

          (1)   Relevant securities owned and/or controlled

          3,756,867*

          3.86%

          (2)   Cash-settled derivatives

          (3)   Stock-settled derivatives (including options) and agreements to purchase/ sell

          Total

          3,756,867*

          3.86%

          *Janus Henderson Group Plc does not have discretion regarding voting decisions in respect 69,093 shares that are included in the total above.

          All interests and all short positions should be disclosed.

          Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

          3.             DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

          Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

          The currency of all prices and other monetary amounts should be stated.

          (a)           Purchases and sales

          Class of relevant

          security

          Purchase/sale

          Number of

          securities

          Price per unit

          (Note 5)

          €0.01 ordinary shares

          Sale

          296

          USD 21.381841

          €0.01 ordinary shares

          Purchase

          23

          USD 21.360000

          Ap29

          (b)           Cash-settled derivative transactions

          • Class of

            relevant

            security

          • Product

            description

            e.g. CFD

          • Nature of dealing

            e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position

          • Number of

            reference

            securities

            (Note 6)

          • Price

            per unit

            (Note 5)

          (c)           Stock-settled derivative transactions (including options)

          (i)            Writing, selling, purchasing or varying

          • Class of

            relevant

            security

          • Product

            description e.g. call

            option

          • Writing, purchasing, selling, varying

            etc.

          • Number

            of

            securities

            to which

            option

            relates

            (Note 6)

          • Exercise

            price per

            unit

          • Type

            e.g.

            American,

            European

            etc.

          • Expiry

            date

          • Option

            money

            paid/

            received per unit

          (ii)           Exercise

          • Class of

            relevant

            security

          • Product

            description

            e.g. call

            option

          • Exercising/

            exercised

            against

          • Number of

            securities

          • Exercise

            price per

            unit

            (Note 5)

          (d)           Other dealings (including transactions in respect of new securities) (Note 3)

          • Class of

            relevant

            security

          • Nature of dealing

            e.g. subscription,

            conversion, exercise

          • Details

          • Price per unit (if

            applicable)

            (Note 5)

          Ap30

          4.             OTHER INFORMATION

          (a)           Indemnity and other dealing arrangements

          • Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.

            Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

          • None

          (b)           Agreements, arrangements or understandings relating to options or derivatives

          • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

          • None

          (c)           Attachments

          • Is a Supplemental Form 8 attached?

          • No

          Date of disclosure

          04 December 2025

          Contact name

          John Baker

          Telephone number

          +44 207 818 3064

          Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

          Ap31

          NOTES ON FORM 8.3

          1.             See the definition of "connected fund manager" in Rule 2.2 of Part A of the Rules.

          2.             See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.

          3.             See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.

          4.             See the definition of "dealing" in Rule 2.1 of Part A of the Rules.

          5.             If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

          6.             See Rule 2.5(d) of Part A of the Rules.

          7.             If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

          For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

          References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

          This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

          RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  ITPKZMGZMDVGKZM

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share
          FastBull
          Copyright © 2025 FastBull Ltd

          728 RM B 7/F GEE LOK IND BLDG NO 34 HUNG TO RD KWUN TONG KLN HONG KONG

          TelegramInstagramTwitterfacebooklinkedin
          App Store Google Play Google Play
          Products
          Charts

          Chats

          Q&A with Experts
          Screeners
          Economic Calendar
          Data
          Tools
          Membership
          Features
          Function
          Markets
          Copy Trading
          Latest Signals
          Contests
          News
          Analysis
          24/7
          Columns
          Education
          Company
          Careers
          About Us
          Contact Us
          Advertising
          Help Center
          Feedback
          User Agreement
          Privacy Policy
          Business

          White Label

          Data API

          Web Plug-ins

          Poster Maker

          Affiliate Program

          Risk Disclosure

          The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.

          No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.

          Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.

          Not Logged In

          Log in to access more features

          FastBull Membership

          Not yet

          Purchase

          Become a signal provider
          Help Center
          Customer Service
          Dark Mode
          Price Up/Down Colors

          Log In

          Sign Up

          Position
          Layout
          Fullscreen
          Default to Chart
          The chart page opens by default when you visit fastbull.com